Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1075844

NS(=O)(=O)N1CCC(NC(=O)Nc2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 11/20 0.48
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
STK4 Q13043 1/20 0.36
STK3 Q13188 1/20 0.36
STK26 Q9P289 1/20 0.36
STK24 Q9Y6E0 1/20 0.36
JAK2 O60674 7/20 0.36
JAK1 P23458 7/20 0.36
TYK2 P29597 7/20 0.36
JAK3 P52333 7/20 0.36
CDK14 O94921 2/20 0.35
CCNY Q8ND76 1/20 0.35
XBP1 P17861 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1074515 0.96 ALK (0.47) ALKSTK4STK3STK26STK24
SCHEMBL1075992 0.95 ALK (0.53) ALKMAPTMEN1NPY1RNPY2R
Trifluoroacetic Acid SCHEMBL4370362 0.94 ALK (0.49) ALKMAPTMEN1NPY1RNPY2R
Trifluoroacetic Acid SCHEMBL4358088 0.92 ALK (0.51) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4361347 0.91 ALK (0.48) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4360613 0.91 ALK (0.48) ALKSTK4STK3STK26STK24
SCHEMBL4370439 0.91 ALK (0.51) ALKSTK4STK3STK26STK24
Trifluoroacetic Acid SCHEMBL4361406 0.90 ALK (0.49) ALKSTK4STK3STK26STK24
SCHEMBL4365429 0.89 ALK (0.54) ALKMAPTSTK4STK3STK26
Trifluoroacetic Acid SCHEMBL1072057 0.89 ALK (0.48) ALKSTK4STK3STK26STK24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885MAPT 3239/4885MEN1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.